Lupus News

The question: In people with lupus, the immune system goes awry and turns on the body.

LA JOLLA, CA, June 29, 2009 The more than 1.5 million Americans with systemic lupus erythematosus suffer from a variety of symptoms that flare and subside, often including painful or swollen joints, extreme fatigue, skin rashes, fever, and kidney problems.

David Stump, HGS's head of drug development, hopes the first PowerPoint slide the biostatistician presents at the results meeting will say success.

The late pop star Michael Jackson led what could only be called an eccentric life.

Q: I was originally diagnosed with rheumatoid arthritis three years ago. Multiple treatments have been ineffective.

The Lupus Foundation of America is seeking proposals for grant funding for research studies on lupus, an unpredictable and potentially fatal autoimmune disease.

Since 2002, David and Tom Gardner have returned 27.92% while the S&P 500 returned -11.55%. Try Stock Advisor free for 30 days.

OXON HILL, MD, June 20, 2009 /Cambridge Who's Who/ -- Edith Morgan-Aultmon, Health Fair Coordinator for the Greater Washington Chapter of the Lupus Foundation of America, Inc., has been recognized by Cambridge Who's Who for showing dedication, leadership and excellence in all aspects of non-profit management.

In some ways, those who battle autoimmune disease are at war with themselves. Among these diseases are such prominent ones as type 1 diabetes, multiple sclerosis, rheumatoid arthritis, lupus, celiac, Crohns disease and Graves' disease.

Main Category: Lupus Also Included In: Anxiety / Stress ; Depression Article Date: 16 Jun 2009 - 1:00 PDT 92.8% of patients with systemic lupus erythematosus suffer anxiety and depression which significantly affects both their physical and emotional quality of life , according to the results of a new study presented today at EULAR 2009, the Annual ...

All lupus patients, as well as family and friends who support them, are welcome.

Human Genome Sciences has reported continuation data from a Phase II study of BENLYSTA showing sustained improvement in patients with active systemic lupus after four years of treatment.

Shares of Human Genome Sciences leaped over 20% to $3.33 in pre-market trading Thursday after the biotech group reported positive Phase II clinical data for its lupus drug candidate Benlysta, also known as belimumab.

Results from an international online survey, carried out by UCB in conjunction with Lupus Europe and the Lupus Foundation of America, the two principal advocacy groups that represent people with lupus, were presented during the EULAR congress at a symposium called, "Lupus - considering the future." Professor David Isenberg , the symposium chairman, ...

Since 2002, David and Tom Gardner have returned 31.59% while the S&P 500 returned -8.69%. Try Stock Advisor free for 30 days.

Moving Status from "Sell" to "Hold" Lupus symptoms have not retreated like Human Genome Science Inc.

Main Category: Lupus Also Included In: Urology / Nephrology ; Immune System / Vaccines ; Biology / Biochemistry Article Date: 12 Jun 2009 - 0:00 PDT DNA vaccination using lupus autoantigens and interleukin-10 has potential as a novel therapy to induce antigen specific tolerance and may help to prevent kidney damage in patients with systemic lupus ...

A phase 2 trial of the drug belimumab in patients with active systemic lupus erythematosus showed positive results, according to the drug company.

Human Genome Sciences Inc. shares jumped on new positive results from a longer-term second-stage study of its lupus drug, though a more stringent test for the Rockville company comes next month when late-stage results are expected to hit the wires.

The side effects are often reversible, but it's important that clinicians be able to recognize the signs.